Conjunctival vs sublingual administration of carteolol 2% eye drops. Ocular hypotensive effects and some systemic parameter changes.
Camerino
L
L
Eye Clinic I, University of Turin.
Gastaldi
C
C
Brogliatti
B
B
Boles Carenini
B
B
D000286:Administration, Sublingual; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000368:Aged; D002354:Carteolol / Q000008:administration & dosage* / Q000009:adverse effects; D002908:Chronic Disease; D003228:Conjunctiva; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D009883:Ophthalmic Solutions; D002354:Carteolol